Navigation Links
Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
Date:5/21/2012

Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's anticipated use of proceeds from the offering, its focus, its research and development programs, and its ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review is uncertain and Arena's applications for regulatory approval of lorcaserin may not be reviewed when or as anticipated; the timing, results, influence and other impact of FDA advisory committee meetings relating to lorcaserin and other drug candidates; the FDA may not comp
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015 Research ... addition of the "Market Assessment of Respiratory ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... respiratory imaging diagnostics market in the ... . The service provides detailed analysis of ...
(Date:5/21/2015)... May 21, 2015  Cardica, Inc. (Nasdaq: CRDC ) ... Greg Watson , the company,s vice president of operations, was ... common stock, at a per share exercise price of $0.43, ... option was granted pursuant to Cardica, Inc.,s Inducement Plan, which ... 2015 under Rule 5653(c)(4) of the Nasdaq Global Market for ...
(Date:5/21/2015)... YORK , 21. Mai 2015 ... DPRX ), ein Unternehmen für ... auf die Entwicklung und Vermarktung von ... konzentriert, kündigte heute eine wissenschaftliche Posterpräsentation ... Phase-III-Zulassungsstudie des Unternehmens vorstellt, OneStep-1 und ...
Breaking Medicine Technology:United States and Europe Respiratory Diagnostics Market Assessment 2015 2Cardica Announces New Employment Inducement Grant 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
... Ala., May 7 BioCryst Pharmaceuticals (Nasdaq: BCRX ... first quarter 2009 financial results will be released on Friday, ... a conference call and Web cast at 8:30 a.m. Eastern ... on the Company,s programs. The call will be led ...
... The Abbott RealTi m e HIV-1 Assay and Abbott ... protocol for viral load testing in HIV/AIDS clinical trials sponsored ... This recommendation was made by the Cross-Network Laboratory Focus Group ... HIV/AIDS clinical trials networks. The LFG recently issued a consensus ...
Cached Medicine Technology:BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009 2HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials 2HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials 3
(Date:5/24/2015)... Scottsdale, Arizona (PRWEB) May 24, 2015 ... hired former Millennial Media strategy executive Jay Krihak ... as Medicx looks to ramp up its expertise ... services of the Pharmaceutical and Health sectors. , ... ad tech executive. Most recently, Krihak led sales ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 Dr. David Benvenuti, ... has just posted a new article to his ... As Dr Benvenuti explained in the fascinating blog, ... plugs in their earlobes. , Known as “gauging,” the technique ... hole, which Dr. Benvenuti said will eventually stretch the holes ...
(Date:5/23/2015)... A live auction will be held to sell ... and other medical facilities around the United States. Various ... surgery, anesthesia, exam and much more. , The live ... 28 starting at 9:00am CDT each day. The equipment is ... Melrose Park, IL 60160. Anyone can participate in the ...
(Date:5/22/2015)... OR (PRWEB) May 22, 2015 Pioneer ... remains at the forefront of designing with reclaimed wood, ... Design in Los Angeles, California. Their newest offerings, Vat ... bring much-anticipated surface and color to America's largest design ... our exhibit at each show, anxious to see and ...
(Date:5/22/2015)... 2015 Following yesterday’s announcement that Ascenta ... US-based health brand Nature’s Way, Marc St-Onge has affirmed ... Ascenta Skin is an integral part of the agreement ... opportunity to further develop Ascenta Skin into a leading ... is a breakthrough, anti-aging skincare supplement featuring 6 active ...
Breaking Medicine News(10 mins):Health News:Medicx Media Solutions Expands Executive Team 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:Ascenta Skin President Announces Plans to Grow Brand 2
... Inc. (TSX: MDS; NYSE: MDZ ), a ... life sciences markets earlier today disclosed that it had ... Technologies business to Danaher Corporation (NYSE: DHR ... announcement, ValueAct Capital and Enterprise Capital Management Inc., two ...
... CHARLES TOWN, W.Va., Sept. 2 ReBuilder Medical Technologies, Inc. (Pink ... from peripheral neuropathy and Peripheral Artery Disease today announced that ... the ReBuilder for pain. , , (Logo: ... U.S. are now using the ReBuilder as their first choice for ...
... , WASHINGTON, Sept. 2 Hollywood star Danny Glover, ... blockbuster Lethal Weapon movies, will be featured on this ... affairs television program that tells the compelling and inspirational stories of ... more than 300 television stations nationwide. , , ...
... Eastern Virginia Medical School,s Strelitz Diabetes Center have been ... Diabetes Research Foundation (JDRF). The center,s research team, ... internal medicine and director of the center, has been ... (12-LO) in damaging insulin-producing beta cells, a condition that ...
... , HARRISBURG, Pa., Sept. 2 United Concordia Dental ... resin fillings -- for its Concordia Flex((R)), Concordia Preferred((R)) and Concordia ... , , "Brokers, employers and members asked ... said Sharon Muscarella, United Concordia senior vice president of sales and ...
... , , , ... Hill-Rom (NYSE :HRC) and Radianse today announced a strategic partnership ... Hill-Rom,s leading NaviCare(R) Nurse Call system. With this move, ... beyond staff tracking to remove financial and technical obstacles for ...
Cached Medicine News:Health News:MDS Announces Voting Support Agreements 2Health News:MDS Announces Voting Support Agreements 3Health News:ReBuilder Medical Technologies, Inc. Announces Unique Arthritic Pain Accessory 2Health News:'Sharing Miracles' Television Program to Feature Award-Winning Hollywood Star Danny Glover 2Health News:'Sharing Miracles' Television Program to Feature Award-Winning Hollywood Star Danny Glover 3Health News:'Sharing Miracles' Television Program to Feature Award-Winning Hollywood Star Danny Glover 4Health News:'Sharing Miracles' Television Program to Feature Award-Winning Hollywood Star Danny Glover 5Health News:'Sharing Miracles' Television Program to Feature Award-Winning Hollywood Star Danny Glover 6Health News:'Sharing Miracles' Television Program to Feature Award-Winning Hollywood Star Danny Glover 7Health News:JDRF award supports study of potential target for blocking type 1 diabetes 2Health News:United Concordia Dental Expands Benefit Options 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4
... a number of assay steps for ... simple to use benchtop device. The ... stand-alone device but also provides easy ... and standard add-on modules provide maximum ...
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi...
Smith & Nephew's CDS System is developed exclusively for discography., Developed exclusively for discography, it is the first system designed to measure true disc pressure and record real-time proce...
The Maxi-Therm® lite hyper-hypothermia water blankets from Cincinnati Sub-Zero take conductive warming and cooling therapy to a new, softer level. These blankets are soft, lightweight, and remai...
Medicine Products: